Education
About Us
Working with TipRanks
Follow Us
Percheron Therapeutics (PERCF)
OTHER OTC:PERCF
Total Valuation
Percheron Therapeutics has a market cap or net worth of $7.04M. The enterprise value is ―.
Market Cap$7.04M
Enterprise Value―
Share Statistics
Percheron Therapeutics has 1,087,437,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,087,437,600
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Percheron Therapeutics’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee―
Profits Per Employee―
Employee Count―
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of Percheron Therapeutics is ―. Percheron Therapeutics’s PEG ratio is ―.
PE Ratio―
PS Ratio0.00
PB Ratio―
Price to Fair Value―
Price to FCF―
Price to Operating Cash Flow―
PEG Ratio―
Income Statement
In the last 12 months, Percheron Therapeutics had revenue of ― and earned -5.81M in profits. Earnings per share was ―.
Revenue―
Gross Profit―
Operating Income-7.61M
Pretax Income―
Net Income-5.81M
EBITDA-7.52M
Earnings Per Share (EPS)―
Cash Flow
In the last 12 months, operating cash flow was ― and capital expenditures ―, giving a free cash flow of ― billion.
Operating Cash Flow―
Free Cash Flow―
Free Cash Flow per Share―
Dividends & Yields
Percheron Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.20
52-Week Price Change0.00%
50-Day Moving Average0.04
200-Day Moving Average0.02
Relative Strength Index (RSI)75.01
Average Volume (3m)333.00
Important Dates
Percheron Therapeutics upcoming earnings date is Aug 27, 2025, TBA Not Confirmed.
Last Earnings DateFeb 19, 2025
Next Earnings DateAug 27, 2025
Ex-Dividend Date―
Financial Position
Percheron Therapeutics as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, Percheron Therapeutics has paid ― in taxes.
Income Tax―
Effective Tax Rate―
Enterprise Valuation
Percheron Therapeutics EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Percheron Therapeutics has ― in cash and marketable securities with 227.40K in debt, giving a net cash position of ― billion.
Cash & Marketable Securities―
Total Debt227.40K
Net Cash―
Net Cash Per Share―
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for Percheron Therapeutics is $0.01, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$0.01
Price Target Upside0.00%
Analyst ConsensusHold
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―